Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by OIS Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by OIS Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Bringing Presbyopia Back to the Forefront: Paul Smith of Orasis on The Rob & Jai Show, an Edition of the OIS Podcast

36:21
 
Share
 

Manage episode 476423532 series 2501544
Content provided by OIS Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by OIS Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this edition of The Rob & Jai Show, Paul Smith, President & COO of Orasis Pharmaceuticals, joins Dr. Rob Rothman and Dr. Jai Parekh for a compelling conversation on his career path and the commercialization of Qlosi™—a novel, FDA-approved, low-dose pilocarpine eye drop for the treatment of presbyopia.

With more than two decades of experience across Alcon, Novartis, and now Orasis, Smith reflects on his unique career trajectory from tech startups to ophthalmic leadership, the importance of cross-functional experience, and how a shared vision with founder & CEO Elad Kedar led him to the helm of a company now reshaping the presbyopia landscape.

In this episode, you'll learn:

  • Why Qlosi™ was formulated at the lowest approved concentration of pilocarpine to prioritize safety, tolerability, and functional vision.
  • How Orasis is differentiating its launch by learning from past category efforts and focusing on real-world expectations and patient needs.
  • The company’s go-to-market strategy, including a hybrid access model and the role of optometry in driving adoption.
  • Why Paul believes innovation in eye care thrives on collaboration, humility, and continuous learning.
  • What makes presbyopia such a powerful entry point into the broader continuum of vision care.

With a clear mission, strong leadership, and a product designed with patients in mind, Orasis is setting a new standard in treating one of the most common unmet needs in eye care.

Don’t miss this thoughtful and inspiring discussion—subscribe to the OIS Podcast today to stay ahead of what’s next in ophthalmic innovation!

  continue reading

421 episodes

Artwork
iconShare
 
Manage episode 476423532 series 2501544
Content provided by OIS Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by OIS Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this edition of The Rob & Jai Show, Paul Smith, President & COO of Orasis Pharmaceuticals, joins Dr. Rob Rothman and Dr. Jai Parekh for a compelling conversation on his career path and the commercialization of Qlosi™—a novel, FDA-approved, low-dose pilocarpine eye drop for the treatment of presbyopia.

With more than two decades of experience across Alcon, Novartis, and now Orasis, Smith reflects on his unique career trajectory from tech startups to ophthalmic leadership, the importance of cross-functional experience, and how a shared vision with founder & CEO Elad Kedar led him to the helm of a company now reshaping the presbyopia landscape.

In this episode, you'll learn:

  • Why Qlosi™ was formulated at the lowest approved concentration of pilocarpine to prioritize safety, tolerability, and functional vision.
  • How Orasis is differentiating its launch by learning from past category efforts and focusing on real-world expectations and patient needs.
  • The company’s go-to-market strategy, including a hybrid access model and the role of optometry in driving adoption.
  • Why Paul believes innovation in eye care thrives on collaboration, humility, and continuous learning.
  • What makes presbyopia such a powerful entry point into the broader continuum of vision care.

With a clear mission, strong leadership, and a product designed with patients in mind, Orasis is setting a new standard in treating one of the most common unmet needs in eye care.

Don’t miss this thoughtful and inspiring discussion—subscribe to the OIS Podcast today to stay ahead of what’s next in ophthalmic innovation!

  continue reading

421 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play